2524 Viewed1105 Downloaded
Comparison of the Immunohistochemical Expression of Caveolin-1 in Endometrial Carcinoma, Endometrial Intraepithelial Neoplasia, Endometrial Hyperplasia, and Normal Endometrium
Received: 23 Aug 2019 | Received in revised form: 29 Nov 2019
Accepted: 29 Nov 2019 | Available online: 29 Nov 2019Duygu AYAZa, Gülden DİNİZb, Sibel DEMİR KEÇECİc, Dudu SOLAKOĞLU KAHRAMANa, Sevil SAYHANa
aPathology Laboratory, İzmir Tepecik Training and Research Hospital,
bDepartment of Pathology, İzmir Democracy University Faculty of Medicine, İzmir, TURKEY
cClinic of Pathology, Manisa Merkez Efendi State Hospital, Manisa, TURKEY
J Clin Obstet Gynecol. 2019;29(4):123-8
DOI: 10.5336/jcog.2019-71119
Article Language: EN
Copyright Ⓒ 2024 by Türkiye Klinikleri. This is an open access article under the CC BY-NC-ND license (
http://creativecommons.org/licenses/by-nc-nd/4.0/)
ABSTRACT
Objective: This retrospective study was designed to evaluate the importance of tissue expressions of caveolin-1 (Cav-1) known as signal regulator in differential diagnosis of endometrial lesions. Material and Methods: A total of 65 patients with normal endometrium (11 proliferative and 10 secretory epithelium, 32.3%), endometrial hyperplasia without atypia (EH) (n=11, 16.9%); atypical endometrial hyperplasia/ endometrioid intraepithelial neoplasia (AEH/EIN) (n=11; 16.9%) and endometrial carcinoma (EC) (n=22; 33.8%) were recruited for the study. Sections prepared from biopsy materials or hysterectomy specimens of the patients were immunohistochemically processed, stained, and examined for the presence of caveolin-1 expression. The positive association between immunohistochemical staining of caveolin-1 and its relationship with characteristic features of lesions and age of the patients were investigated. Results: The mean age of the patients was 49.1± 8.5 years. Stromal fibroblasts were positively stained for Cav-1 in 26 (40%) cases, and stromal expressions of Cav-1. Stromal Cav-1 expressions were detected in indicated cases with EH (36.4%), EIM (27.3%), and EC (68.2%), while only in 19% of normal endometrial biopsy specimens. It was determined that if the tumor becomes more invasive, then its stromal Cav-1 expression reaches to statistically significantly higher levels (p=0.001). Conclusion: Our findings demonstrated that stromal Cav-1 expression could be used as a marker for malignancy and invasiveness of endometrial neoplasms.
REFERENCES:- Lisanti MP, Scherer PE, Tang Z, Sargiacomo M. Caveolae, caveolin and caveolin-rich membrane domains: a signaling hypothesis. Trends Cell Biol. 1994;4(7):231-5. [Crossref] [PubMed]
- Hurlstone AF, Reid G, Reeves JR, Fraser J, Strathdee G, Rahilly M, et al. Analysis of the Caveolin-1 gene at human chromosome 7q31.1 in primary tumors and tumor-derived cell lines. Oncogene. 1999;18(10):1881-90. [Crossref] [PubMed]
- Razani B, Woodman SE, Lisanti MP. Caveolae: from cell biology to animal physiology. Pharmacol Rev. 2002;54(3):431-67. [Crossref] [PubMed]
- Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6(5):392-401. [Crossref] [PubMed]
- Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol. 2009;174(6):2023-34. [Crossref] [PubMed] [PMC]
- Huang CF, Yu GT, Wang WM, Liu B, Sun ZJ. Prognostic and predictive values of SPP1, PAI and caveolin-1 in patients with oral squamous cell carcinoma. Int J Clin Exp Pathol. 2014;7(9):6032-9. [PubMed]
- Chatterjee M, Ben-Josef E, Thomas DG, Morgan MA, Zalupski MM, Khan G, et al. Caveolin-1 is associated with tumor progression and confers a multi-modality resistance phenotype in pancreatic cancer. Sci Rep. 2015;5:10867. [Crossref] [PubMed] [PMC]
- Sayhan S, Diniz G, Karadeniz T, Ayaz D, Kahraman DS, Gokcu M, et al. Expression of caveolin-1 in peritumoral stroma is associated histological grade in ovarian serous tumors. Ginekol Pol. 2015;6(6):424-8. [Crossref] [PubMed]
- Eliyatkin N, Aktas S, Diniz G, Ozgur HH, Ekin ZY, Kupelioglu A. Expression of stromal Caveolin- 1 may be a predictor for aggressive behaviour of breast cancer. Pathol Oncol Res. 2018;24(1):59-65. [Crossref] [PubMed]
- Aydın HA, Bayramoğlu Z, Erdoğan G, Peştereli E, Şimşek T. Comparison oft he immunohistochemical staining of lumican in endometrioid-type endometrial cancer and endometrial intraepithelial neoplasias. JCOG. 2019;29(2):50-6. [Crossref]
- Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 2009;16(1):8-13. [Crossref] [PubMed]
- Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO classification of tumours of female reproductive organs. In: Zaino R, Carinelli SG, Ellenson LH, Eng G, Karabuchi H, Kanishi I, eds. Epithelial Tumours and Precursors. 4th ed. France: IARC; 2014. p.125-35.
- Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: Gynecologic Oncology Group study. Cancer. 2006;106(4):812-9. [Crossref] [PubMed]
- Diaz-Valdivia N, Bravo D, Huerta H, Henriquez S, Gabler F, Vega M, et al. Enhanced caveoli-1 expression increases migration, anchorage-independent growth and invasion of endometrial adenocarcinoma cells. BMC Cancer. 2015;15(463):1-11. [Crossref] [PubMed] [PMC]
- Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene. 1998;16(11):1391-7. [Crossref] [PubMed]
- Bender FC, Reymond MA, Bron C, Quest AF. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res. 2000;60(20):5870-8. [PubMed]
- Fiucci G, Ravid D, Reich R, Liscovitch M. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene. 2002;21(15):2365-75. [Crossref] [PubMed]
- Quest AF, Leyton L, Párraga M. Caveolins, caveolae, and lipid rafts in cellular transport, signaling, and disease. Biochem Cell Biol. 2004;82(1):129-44. [Crossref] [PubMed]
- Nú-ez-Wehinger S, Ortiz RJ, Díaz N, Díaz J, Lobos-González L, Quest AF. Caveolin-1 in cell migration and metastasis. Curr Mol Med. 2014;14(2):255-74. [Crossref] [PubMed]
- Ayala G, Morello M, Frolov A, You S, Li R, Rosati F, et al. Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression. J Pathol. 2013;231(1):77-87. [Crossref] [PubMed] [PMC]
- Tuxhorn JA, McAlhany SJ, Dang TD, Ayala GE, Rowley DR. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res. 2002;62(11):3298-307. [PubMed]
- Campbell L, Gumbleton M, Griffiths DF. Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. Br J Cancer. 2003;89(10):1909-13. [Crossref] [PubMed] [PMC]
- Paskaš S, Janković J, Marečko I, Išić Denčić T, Tatić S, Cvejić D, et al. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status. Otolaryngol Head Neck Surg. 2014;150(2):201-9. [Crossref] [PubMed]
- Senetta R, Stella G, Pozzi E, Sturli N, Massi D, Cassoni P. Caveolin-1 as a promoter of tumour spreading: when, how, where and why. J Cell Mol Med. 2013;17(3):325-36. [Crossref] [PubMed] [PMC]
- Goetz JG, Minguet S, Navarro-Lérida I, Lazcano JJ, Samaniego R, Calvo E, et al. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell. 2011;146(1):148-63. [Crossref] [PubMed] [PMC]
- Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 2006;24(29):4783-91. [Crossref] [PubMed] [PMC]